Emerging therapies for AMD management

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials

In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint

Developing technology may offer marked improvements in surgical precision

The company received marketing authorisation approval in the EU earlier this year

The endorsement follows FDA approval in the United States this summer

In this case study, a patient with recently diagnosed cancer demonstrated significant improvement for ocular symptoms of BDUMP following plasmapheresis